#ONJCRI
Dr Michael Buchert and PhD student Birhanu Jemere represented ONJCRI at CSIRO's ON Prime Program, presenting their project "The Phage Factor" alongside La Trobe University collaborators Prof Joseph Tucci and Dr Mwila Kabwe.

➡️ https://ow.ly/Xulf5101XeU
#ONPrimeProgram #CSIRO #ThePhageFactor
October 30, 2026 at 2:00 AM
ONJCRI is proud to lead the DIVA trial, a Phase 1b clinical trial evaluating whether vididencel can help AML patients stay leukaemia-free for longer.
A big step for novel immunotherapy access in AML.
➡️ https://ow.ly/1gLM50ZYhZA

#AML #Immunotherapy #ClinicalTrials #LeukaemiaResearch
October 18, 2026 at 11:20 PM
🛫 Dr Shiyao Li and Dr Dilshan Gunasinghe receive the ONJCRI Postdoc Domestic Travel Award, a key initiative led by our Postdoc Committee enabling our postdoctoral researchers to attend key Australian conferences and meetings.

#PostdoctoralResearch #AcademicTravel
September 22, 2026 at 4:25 AM
ONJCRI, WEHI and Genentech researchers used a new CRISPR guide RNA library (Partita) and discovered that:
➡️ Switching on the Irx5 gene allowed cancer cells to survive venetoclax
️➡️ Runx2, Runx3, and Csf1r genes accelerate MYC-driven lymphoma

📘 https://ow.ly/XmsJ50ZO8xW
#CRISPRActivation #Lymphoma
September 21, 2026 at 12:00 AM
The finding was published in Science Advances , following a preprint on bioRxiv from July 2025.
Partita: the CRISPR platform that reveals why lymphoma resists venetoclax - Sinaptica
A team of researchers from the Olivia Newton-John Cancer Research Institute (ONJCRI), the Walter and Eliza Hall Institute (WEHI), and Genentech, in collaboratio
sinapti.ca
September 19, 2026 at 1:11 AM
El hallazgo se publicó en Science Advances , tras un preprint en bioRxiv de julio de 2025.
Partita: la plataforma CRISPR que revela por qué el linfoma resiste al venetoclax - Sinaptica
Un equipo de investigadores del Olivia Newton-John Cancer Research Institute (ONJCRI), el Walter and Eliza Hall Institute (WEHI) y Genentech, en colaboración co
sinapti.ca
September 19, 2026 at 1:11 AM
The first Australian participant has been enrolled in the global VIGOR trial, sponsored by ONJCRI in collaboration with COGNO in Australia.

The trial will investigate vorasidenib maintenance treatment in people with IDH-mutant grade 2/3 astrocytoma.

➡️ https://ow.ly/SnyR50ZMpoj

#VIGORTrial #Glioma
September 16, 2026 at 11:00 PM
🌏 Join us for an exclusive event focused on the cutting-edge technologies that enable research at ONJCRI to mark World Cancer Research Day.

🎟️ https://ow.ly/YrCI50ZJ2uW

#FreeEvent #CancerResearch #STEM #WorldCancerResearchDay #Nanomedicine #GeneEditing #AI
September 7, 2026 at 2:00 AM
ONJCRI laboratory head A/Prof Lisa Mielke will join the ‘hunt’ for the causes behind the rising numbers of early-onset bowel cancer through the new Centre of Research Excellence ARTEMIS.

➡️ Learn more: https://ow.ly/rHIl50ZIvuw

#BowelCancerResearch #EarlyOnsetCancer
September 3, 2026 at 2:00 AM
ONJCRI and Adelaide University researchers found that TNBC patients with low levels of the miR-342 molecule and high activity of the E2F pathway were more likely to develop metastatic disease.

➡️ https://ow.ly/Suux50ZH53j

@adelaideuni.bsky.social #TNBC #CancerResearch
August 31, 2026 at 5:00 AM
Coming up tomorrow (Tuesday) at noon Pacific — using #CRISPR to study #cancer #lymphoma! Join us in person or on Zoom for a seminar from Marco Herold, CEO @onjcri.org.au & head of La Trobe University’s School of Cancer Medicine. More info here: ow.ly/YrtV50VNfEQ
May 5, 2025 at 8:27 PM
ONJCRI and La Trobe University (LaTrobeUni) researchers have found that even a modest reduction in BECLIN1 leads to a significant increase in gut inflammation, resulting in greater susceptibility to disease and complications over time
➡️ https://ow.ly/nP0o50ZmgwB
#beclin1 #bowelcancer #IBD #autophagy
July 13, 2026 at 2:00 AM
🧬 ~30% of colorectal tumours lose MHC-I, the "ID tag" immune cells use to spot cancer. ONJCRI PhD candidate Andrew Li shows γδ T cells are significantly increased in these "invisible" tumours, opening the door for new immunotherapies. Open access: https://ow.ly/EefF50Zc6WB
#Cancer #TCells #MHC
June 19, 2026 at 2:00 AM
A new review paper by ONJCRI researchers Anamika Saini and Dr Shiyao Li investigates how the biomolecular corona that forms on RNA-lipid nanoparticles shapes their cargo delivery behaviour.

➡️ ow.ly/mOhR50Z5rpA (ACS Nano @pubs.acs.org)

#LipidNanoparticles #Nanomedicine
June 3, 2026 at 4:17 AM
Researchers from ONJCRI, WEHI and Peter Mac have discovered that DNA barcoding can be used to track cancer cells in solid and liquid biopsies.

In a world-first, the team were able to detect the DNA barcodes shed by the primary tumour in plasma samples.

➡️ https://ow.ly/fcK550Yc0WN
February 11, 2026 at 10:00 PM
🌏 Last night we marked World Cancer Day with a public event at ONJCRI, co-hosted with La Trobe Institute for Molecular Science (LIMS).
Our community explored cutting-edge cancer research and heard from an inspiring panel.
Thank you to all who joined us!
Read more: https://ow.ly/U6Hp50Y98im
February 5, 2026 at 6:00 AM
ONJCRI is thrilled to announce that Prof Eliza Hawkes and Prof Hui Gan have received MRFF Clinical Trials Activity funding to lead new and impactful clinical trials for blood and brain cancer patients.

➡️ https://ow.ly/mEgi50XZUuX

#ClinicalTrials #CancerTrials #Glioblastoma #Lymphoma #MRFF
January 20, 2026 at 2:15 AM
ONJCRI and WEHI (The Walter and Eliza Hall Institute of Medical Research) researchers have discovered that the TAK1 gene acts like a molecular safety switch, protecting cancer cells from attack by the immune system.

➡️ Read more: https://ow.ly/YtVW50XLgyq

#TAK1 #CancerResearch #Immunotherapy
December 19, 2025 at 11:00 PM
Stomach cancer is often caught late and hard to treat, but Dr Lisa Mielke's team at ONJCRI is changing that. By uncovering how the nervous system fuels stomach & bowel cancer growth, they are opening doors to new treatments.
Learn more: https://ow.ly/Lt9x50Xve2T

#StomachCancer #BowelCancer
November 21, 2025 at 4:00 AM
We are delighted to share that A/Prof Peter Janes and A/Prof Doug Fairlie have received Pankind 2025 Research Grants, allowing them to make strides in their pancreatic cancer research.

➡️ Read more: https://ow.ly/Coqq50XsqUl

#PancreaticCancer #CancerResearch #ResearchGrants #ONJCRI
November 18, 2025 at 4:00 AM
Significant new results from ONJCRI’s Phase II rare cancer clinical trial on combination immunotherapy in dMMR/MSI-H non-colorectal cancers have been published in @jamaoncology.com.

➡️ Learn more: jamanetwork.com/journals/jam...

#RareCancers #RareCancerTrial #ClinicalTrials #ONJCRI
November 14, 2025 at 2:14 AM
ONJCRI researchers have found that differentiation grade does not change significantly following cancer spread, suggesting that studying the primary tumour alone will be sufficient to understand the metastasis in most cases.

➡️ Full paper: https://ow.ly/SK0T50XmUct

#ColorectalCancer #CancerResearch
November 6, 2025 at 12:00 AM
ONJCRI was delighted to host our third Science Meets Art exhibition, welcoming members of the community, patient advocates and our supporters.

A huge thank you to the North East Community Fund, the artists and the dedicated Committee who made this event come to life!

➡️ https://ow.ly/YGyK50XmSni
November 5, 2025 at 4:00 AM
ONJCRI joins AAMRI in calling on the Federal Government to release the full MRFF in the 26–27 Federal Budget.

The MRFF was created to deliver $1 billion every year for lifesaving research, but currently, only about $650 million is being released.

Visit aamri.org.au/mrff/

#releasethefullMRFF
November 2, 2025 at 10:28 PM
ONJCRI researchers have linked two nervous system components to bowel cancer growth, creating promising new avenues for treatment with existing approved migraine therapies.

The findings were published in The BMJ Oncology today.

➡️ https://ow.ly/PCFE50XfWVh

#BowelCancer #Neuropeptides #ONJCRI
October 24, 2025 at 6:30 AM